New study tracks hidden autoimmune risks in cancer immunotherapy
NCT ID NCT04220034
First seen Dec 16, 2025 · Last updated May 22, 2026 · Updated 24 times
Summary
This study looked at 183 cancer patients treated with checkpoint inhibitors to see how often they develop autoantibodies (immune system markers that can attack the body) and related autoimmune diseases. The goal was to better understand and monitor these side effects. No new treatment was tested; instead, researchers observed patients over time to gather information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ADVERSE EFFECTS OF ANTI-NEOPLASIC DRUG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chu Reims
Reims, 51092, France
Conditions
Explore the condition pages connected to this study.